11/7
02:25 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
11/7
02:25 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
11/7
12:45 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
11/7
12:45 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
11/7
09:07 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
11/7
08:36 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $205.00 price target on the stock.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $205.00 price target on the stock.
11/7
07:12 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating. They now have a $167.00 price target on the stock, up previously from $152.00.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating. They now have a $167.00 price target on the stock, up previously from $152.00.
11/7
06:46 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
11/7
06:10 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
11/7
06:10 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
10/21
10:04 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $182.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $182.00 price target on the stock.
10/21
10:04 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $182.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $182.00 price target on the stock.
10/21
09:59 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
10/21
09:59 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
10/21
06:58 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
10/21
06:58 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
10/14
08:41 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $205.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $205.00 price target on the stock.
10/14
06:42 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
10/14
06:42 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
10/10
09:36 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $150.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $150.00 price target on the stock.
10/10
09:36 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $150.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $150.00 price target on the stock.
10/10
09:00 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
10/10
09:00 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
10/4
11:19 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
10/4
11:19 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT